Cardiac RNAi therapy using RAGE siRNA/deoxycholic acid-modified polyethylenimine complexes for myocardial infarction

Biomaterials

Volumn 35, Issue 26, 2014, Pages 7562-7573

  Hong, Jueun ^a,b   Ku, Sook Hee ^c   Lee, Min Sang ^d   Jeong, Ji Hoon ^c,d   Mok, Hyejung ^e   Choi, Donghoon ^a   Kim, Sun Hwa ^c  

^a Yonsei University College of Medicine   (South Korea)

^b Korea Testing and Research Institute   (South Korea)

^c Korea Institute of Science and Technology   (South Korea)

^d Sungkyunkwan University   (South Korea)

^e Konkuk University   (South Korea)

Author keywords

Deoxycholic acid modified polyethylenimine; Myocardial ischemia reperfusion injury; RAGE siRNA; SiRNA delivery

Indexed keywords

CELL DEATH;

ADVANCED GLYCATION END PRODUCTS; HYDROPHOBIC INTERACTIONS; LEFT VENTRICULAR REMODELING; MYOCARDIAL ISCHEMIA-REPERFUSION INJURIES; POLYETHYLENIMINES; RAGE SIRNA; SIRNA DELIVERY; VENTRICULAR REMODELING;

RNA;

ADVANCED GLYCATION END PRODUCT RECEPTOR; DEOXYCHOLIC ACID; POLYETHYLENEIMINE; SMALL INTERFERING RNA; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; IMMUNOGLOBULIN RECEPTOR;

APOPTOSIS; ARTICLE; CYTOKINE RELEASE; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE SILENCING; HEART INFARCTION; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE REMODELING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR WEIGHT; PRIORITY JOURNAL; RNA INTERFERENCE; THERAPY EFFECT; ANALOGS AND DERIVATIVES; ANIMAL; CELL LINE; GENETIC TRANSFECTION; GENETICS; MALE; METABOLISM; MYOCARDIAL REPERFUSION INJURY; PATHOLOGY; RAT; SPRAGUE DAWLEY RAT;

RATTUS;

ANIMALS; CELL LINE; DEOXYCHOLIC ACID; MALE; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; POLYETHYLENEIMINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, IMMUNOLOGIC; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84902551474     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.05.025     Document Type: Article

References (37)

1. IHME The global burden of disease: generating evidence, guiding policy 2013, Institute for Health Metrics and Evaluation, Seattle, WA.
2. Frangogiannis N.G. Regulation of the inflammatory response in cardiac repair. Circ Res 2012, 110:159-173.
3. Bonvini R.F., Hendiri T., Camenzind E. Inflammatory response post-myocardial infarction and reperfusion: a new therapeutic target?. Eur Heart J Suppl 2005, 7:I27-I36.
4. Steffens S., Montecucco F., Mach F. The inflammatory response as a target to reduce myocardial ischaemia and reperfusion injury. Thromb Haemost 2009, 102:240-247.
5. Krishnamurthy P., Lambers E., Verma S., Thorne T., Qin G., Losordo D.W., et al. Myocardial knockdown of mRNA-stabilizing protein HuR attenuates post-MI inflammatory response and left ventricular dysfunction in IL-10-null mice. FASEB J 2010, 24:2484-2494.
6. Tassell B.W.V., Seropian I.M., Toldo S., Salloum F.N., Smithson L., Varma A., et al. Pharmacologic inhibition of myeloid differentiation factor 88 (MyD88) prevents left ventricular dilation and hypertrophy after experimental acute myocardial infarction in the mouse. JCardiovasc Pharmacol 2010, 55:385-390.
7. Hofmann M.A., Drury S., Fu C., Qu W., Taguchi A., Lu Y., et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for s100/calgranulin polypeptides. Cell 1999, 97:889-901.
8. Rouhiainen A., Kuja-Panula J., Wilkman E., Pakkanen J., Stenfors J., Tuominen R.K., et al. Regulation of monocyte migration by amphoterin (HMGB1). Blood 2004, 104:1174-1182.
9. Yeh C.-H., Sturgis L., Haidacher J., Zhang X.-N., Sherwood S.J., Bjercke R.J., et al. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-κB transcriptional activation and cytokine secretion. Diabetes 2001, 50:1495-1504.
10. Taguchi A., Blood D.C., del Toro G., Canet A., Lee D.C., Qu W., et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000, 405:354-360.
11. Huang J.-S., Guh J.-Y., Chen H.-C., Hung W.-C., Lai Y.-H., Chuang L.-Y. Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. JCell Biochem 2001, 81:102-113.
12. Bucciarelli L.G., Kaneko M., Ananthakrishnan R., Harja E., Lee L.K., Hwang Y.C., et al. Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury. Circulation 2006, 113:1226-1234.
13. Andrassy M., Volz H.C., Igwe J.C., Funke B., Eichberger S.N., Kaya Z., et al. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 2008, 117:3216-3226.
14. Shang L., Ananthakrishnan R., Li Q., Quadri N., Abdillahi M., Zhu Z., et al. RAGE modulates hypoxia/reoxygenation injury in adult murine cardiomyocytes via JNK and GSK-3β signaling pathways. PLoS One 2010, 5:e10092.
15. Tsoporis J.N., Izhar S., Leong-Poi H., Desjardins J.-F., Huttunen H.J., Parker T.G. S100B interaction with the receptor for advanced glycation end products (RAGE): a novel receptor-mediated mechanism for myocyte apoptosis postinfarction. Circ Res 2010, 106:93-101.
16. Bucciarelli L.G., Ananthakrishnan R., Hwang Y.C., Kaneko M., Song F., Sell D.R., et al. RAGE and modulation of ischemic injury in the diabetic myocardium. Diabetes 2008, 57:1941-1951.
17. Aleshin A., Ananthakrishnan R., Li Q., Rosario R., Lu Y., Qu W., et al. RAGE modulates myocardial injury consequent to LAD infarction via impact on JNK and STAT signaling in a murine model. Am J Physiol Heart Circ Physiol 2008, 294:H1823-H1832.
18. Candido R., Forbes J.M., Thomas M.C., Thallas V., Dean R.G., Burns W.C., et al. Abreaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 2003, 92:785-792.
19. Arumugam T., Simeone D.M., Schmidt A.M., Logsdon C.D. S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). JBiol Chem 2004, 279:5059-5065.
20. Xu Y., Toure F., Qu W., Lin L., Song F., Shen X., et al. Advanced glycation end product (AGE)-receptor for AGE (RAGE) signaling and up-regulation of Egr-1 in hypoxic macrophages. JBiol Chem 2010, 285:23233-23240.
21. Ruponen M., Rönkkö S., Honkakoski P., Pelkonen J., Tammi M., Urtti A. Extracellular glycosaminoglycans modify cellular trafficking of lipoplexes and polyplexes. JBiol Chem 2001, 276:33875-33880.
22. Lu Q.L., Bou-Gharios G., Partridge T.A. Non-viral gene delivery in skeletal muscle: a protein factory. Gene Ther 2003, 10:131-142.
23. Kim D., Lee D., Jang Y.L., Chae S.Y., Choi D., Jeong J.H., et al. Facial amphipathic deoxycholic acid-modified polyethyleneimine for efficient MMP-2 siRNA delivery in vascular smooth muscle cells. Eur J Pharm Biopharm 2012, 81:14-23.
24. Kim D., Hong J., Moon H.H., Nam H.Y., Mok H., Jeong J.H., et al. Anti-apoptotic cardioprotective effects of SHP-1 gene silencing against ischemia-reperfusion injury: use of deoxycholic acid-modified low molecular weight polyethyleneimine as a cardiac siRNA-carrier. JControl Release 2013, 168:125-134.
25. Jang Y.L., Yun U.J., Lee M.S., Kim M.G., Son S., Lee K., et al. Cell-penetrating peptide mimicking polymer-based combined delivery of paclitaxel and siRNA for enhanced tumor growth suppression. Int J Pharm 2012, 434:488-493.
26. Chae S.Y., Kim H.J., Lee M.S., Jang Y.L., Lee Y., Lee S.H., et al. Energy-independent intracellular gene delivery mediated by polymeric biomimetics of cell-penetrating peptides. Macromol Biosci 2011, 11:1169-1174.
27. Fischer D., Bieber T., Li Y., Elsässer H.-P., Kissel T.A. Novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity. Pharm Res 1999, 16:1273-1279.
28. Yan S.F., Ramasamy R., Schmidt A.M. The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease. Expert Rev Mol Med 2009, 11:e9.
29. Saito Y., Higuchi Y., Kawakami S., Yamashita F., Hashida M. Immunostimulatory characteristics induced by linear polyethyleneimine-plasmid DNA complexes in cultured macrophages. Hum Gene Ther 2009, 20:137-145.
30. Yan S.F., Yan S.D., Ramasamy R., Schmidt A.M. Tempering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation. Ann Med 2009, 41:408-422.
31. Ramasamy R., Vannucci S.J., Yan S.S.D., Herold K., Yan S.F., Schmidt A.M. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 2005, 15:16R-28R.
32. Zeng S., Feirt N., Goldstein M., Guarrera J., Ippagunta N., Ekong U., et al. Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice. Hepatology 2004, 39:422-432.
33. Zhai D.-X., Kong Q.-F., Xu W.-S., Bai S.-S., Peng H.-S., Zhao K., et al. RAGE expression is up-regulated in human cerebral ischemia and pMCAO rats. Neurosci Lett 2008, 445:117-121.
34. Muhammad S., Barakat W., Stoyanov S., Murikinati S., Yang H., Tracey K.J., et al. The HMGB1 receptor RAGE mediates ischemic brain damage. JNeurosci 2008, 28:12023-12031.
35. Leuschner F., Dutta P., Gorbatov R., Novobrantseva T.I., Donahoe J.S., Courties G., et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol 2011, 29:1005-1010.
36. Sugano M., Tsuchida K., Hata T., Makino N. RNA interference targeting SHP-1 attenuates myocardial infarction in rats. FASEB J 2005, 19:2054-2056.
37. Pfeffer M.A., Pfeffer J.M., Fishbein M.C., Fletcher P.J., Spadaro J., Kloner R.A., et al. Myocardial infarct size and ventricular function in rats. Circ Res 1979, 44:503-512.